Abstract 2073P
Background
Medical cannabis is extensively used by Israeli cancer patients, mostly in the form of natural extracts. We've previously shown that cannabis can alleviate symptoms of Oxaliplatin induced CIPN. Yet, it is still unknown which cannabis component, either tetrahydrocannabinol (THC) or cannabidiol (CBD) contribute to this effect and at which dose.
Methods
A database of 5,063 medical records consecutive patients of medical cannabis clinic ('Tikun Olam') was reviewed. 802 patients reported CIPN related symptoms and 751 met inclusion criteria were included in the analysis. Data included questionnaires regarding Patient Reported Outcome (PROM), Activities of Daily Living (ADL) and Quality of Life (QOL) filled before and six months after cannabis use. Four CIPN symptoms were observed. Improvement was defined as positive change from baseline score. Two patients' clusters were identified using k-mean clustering method to study the association between THC, CBD and change in symptoms, ADL and QOL: CBDhigh/ THClow and THChigh/ CBDlow doses.
Results
Symptoms frequency before cannabis use: paresthesia (549pts, 73%), burning sensation (358pts, 48%), numbness (235pts, 31%) and cold sensation (146pts, 19%). After cannabis use improvement reported in paresthesia (320pts, 58%), burning sensation (217pts, 60%), numbness (112pts, 47%) and cold sensation (67pts, 45%). Burning and cold sensation improvement was 37% and 15% in THChigh compare to 27% and 8% in CBDhigh cluster (p=0.02 and p=0.008, respectively). ADL and QOL change were higher in THChigh cluster (p=0.03 and p=0.006, respectively).
Conclusions
The use of natural extracts of cannabis can effectively alleviate CIPN symptoms and improve both QOL and ADL with suggested advantage to high THC levels. Further analysis is required to better correlate specific symptoms to specific components.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Institutional Review Board - Tel Aviv Medical Center.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2086P - Management of opioids use disorder in cancer survivors
Presenter: Khalida Berkane
Session: Poster session 06
2087P - Impact of cancer pain on quality of life and financial well-being: A cross-sectional study on symptom management
Presenter: Raffaele Giusti
Session: Poster session 06
2088P - Management of cancer treatment-induced bone loss in patients with breast and hormone sensitive prostate cancer: AIOM survey among Italian oncologists
Presenter: Anna Amela Valsecchi
Session: Poster session 06
2090P - Management of trastuzumab deruxtecan-related nausea and vomiting in real-world practice
Presenter: Luca Licata
Session: Poster session 06
2091P - Dermocosmetics in management of cancer-related skin toxicities: International expert consensus highlighting the key role of oncology nurses
Presenter: Pascale Dielenseger
Session: Poster session 06
2092P - Bone loss in premenopausal Algerian women treated with chemotherapy for early-stage of breast cancer: Evaluation by DXA and identification of associated risk factors
Presenter: MACHEROUM Fatma zohra
Session: Poster session 06
2093P - Bioelectrical Impedance phase angle and obesity as a prognostic indicator in metastatic gastric cancer patients receiving second-line chemotherapy
Presenter: SangUk Han
Session: Poster session 06
2094P - A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant and olanzapine for highly emetogenic chemotherapy in breast cancer
Presenter: Shinya Takada
Session: Poster session 06
2095P - Cancer rehabilitation program for cancer-related fatigue
Presenter: Aizhan Bekisheva
Session: Poster session 06